OncoTherapy Science Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	2,089	833	527	1,117	1,836
Cash & Short-Term Investments	2,089	833	527	1,117	1,836
Cash Growth	150.78%	58.06%	-52.82%	-39.16%	-36.67%
Accounts Receivable	103	98	35	123	399
Other Receivables	-	-	153	-	-
Receivables	103	98	188	123	399
Inventory	62	78	73	99	231
Other Current Assets	55	96	29	83	134
Total Current Assets	2,309	1,105	817	1,422	2,600
Long-Term Investments	49	49	49	89	84
Other Long-Term Assets	1	1	1	-	1
Total Assets	2,359	1,155	867	1,511	2,685
Current Income Taxes Payable	142	163	141	318	558
Other Current Liabilities	27	164	218	291	46
Total Current Liabilities	169	327	359	609	604
Other Long-Term Liabilities	49	100	155	48	102
Total Liabilities	218	427	514	657	706
Common Stock	50	50	50	789	789
Additional Paid-In Capital	29,839	27,516	26,322	24,793	24,793
Retained Earnings	-27,818	-26,908	-26,092	-24,804	-23,686
Comprehensive Income & Other	70	70	73	76	83
Total Common Equity	2,141	728	353	854	1,979
Shareholders' Equity	2,141	728	353	854	1,979
Total Liabilities & Equity	2,359	1,155	867	1,511	2,685
Net Cash (Debt)	2,089	833	527	1,117	1,836
Net Cash Growth	150.78%	58.06%	-52.82%	-39.16%	-36.67%
Net Cash Per Share	6.36	3.19	2.48	5.80	9.79
Filing Date Shares Outstanding	383.64	277.64	239.34	206.64	192.64
Total Common Shares Outstanding	383.64	271.64	217.64	192.64	192.64
Working Capital	2,140	778	458	813	1,996
Book Value Per Share	5.58	2.68	1.62	4.43	10.27
Tangible Book Value	2,141	728	353	854	1,979
Tangible Book Value Per Share	5.58	2.68	1.62	4.43	10.27